tremelimumab,durvalumab,Sorafenib
AstraZeneca,Pfizer
['sorafenib']
 would be interesting to know how many of the long-term survivors in the sorafenib arm received io in subsequent lines
Hepatologist @ Medical University of Vienna with a special interest in liver cancer